Perspectives in Thoracic Oncology / UNI-MED Science (PDF)

1. Adjuvant chemotherapy in NSCLC 14 1.1. Recent adjuvant chemotherapy trials 14 1.2. The LACE pooled analysis 15 1.3. Which stages should benefit from adjuvant chemotherapy? 15 1.4. The updated individual data-based meta-analysis 15 1.5. Selection by age, histology or type of surgery 16 1.6. Targeted therapies 16 1.7. Prognostic/predictive biomarkers 16 1.8. Vaccines 17 1.9. References 17 2. Customized chemotherapy 22 2.1. DNA repair pathways and potential predictive markers of response to platinum-based chemotherapy 22 2.2. Current clinical data on customized approach to platinum-based chemotherapy 23 2.3. Gemcitabine and pemetrexed as a platinum partner 24 2.4. What is the role of antimicrotubule agents in the perspective of customized chemotherapy in NSCLC? 26 2.5. References 27 3. Epidermal growth factor receptor tyrosine kinase inhibitors 30 3.1. EGFR TKI as first line therapy 30 3.2. EGFR TKI as maintenance therapy 31 3.3. EGFR TKI as second/third line therapy 32 3.4. EGFR TKI as adjuvant therapy 32 3.5. Resistance to EGFR TKI 33 3.6. References 34 4. Anti-angiogenesis 38 4.1. Angiogenesis 38 4.2. Anti-VEGF antibodies 38 4.3. VEGF trap 39 4.4. Tyrosine kinase inhibitors 39 4.5. Sorafenib 40 4.6. Sunitinib 40 4.7. Vandetanib 40 4.8. BIBF 1120 40 4.9. Cediranib 40 4.10. Motesanib 41 4.11. Axitinib and pazopanib 41 4.12. Biomarkers 41 4.13. References 42 5. New drug targets 44 5.1. ALK as a target 44 5.2. HGF/MET pathway 50 5.3. SRC kinase 51 5.4. IGF-1R pathway 51 5.5. PI3K/Akt/mTOR pathway 53 5.6. MAPK pathway 54 5.7. Histone deacetylase pathway 55 5.8. Heat Shock Protein 90 (HSP90) pathway 56 5.9. Sonic hedgehog pathway 57 5.10. BCL-2 pathway 57 5.11. JAK/STAT pathway 58 5.12. LKB1/STK11 pathway 58 5.13. Immunotherapy for lung cancer 59 5.14. References 61 6. Small cell lung cancer (SCLC) 68 6.1. Genetics and pathology 68 6.2. Clinical presentation 68 6.3. Staging and evaluation 69 6.4. Management of LS-SCLC 69 6.5. Prophylactic cranial irradiation 72 6.6.

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.